KR102958419B1 - S1p₁ 수용체와 관련된 병태의 치료 방법 - Google Patents

S1p₁ 수용체와 관련된 병태의 치료 방법

Info

Publication number
KR102958419B1
KR102958419B1 KR1020217024973A KR20217024973A KR102958419B1 KR 102958419 B1 KR102958419 B1 KR 102958419B1 KR 1020217024973 A KR1020217024973 A KR 1020217024973A KR 20217024973 A KR20217024973 A KR 20217024973A KR 102958419 B1 KR102958419 B1 KR 102958419B1
Authority
KR
South Korea
Prior art keywords
compound
delete delete
individual
hydrate
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217024973A
Other languages
English (en)
Korean (ko)
Other versions
KR20210113298A (ko
Inventor
스네할 나이크
Original Assignee
아레나 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69467760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102958419(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아레나 파마슈티칼스, 인크. filed Critical 아레나 파마슈티칼스, 인크.
Publication of KR20210113298A publication Critical patent/KR20210113298A/ko
Application granted granted Critical
Publication of KR102958419B1 publication Critical patent/KR102958419B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
KR1020217024973A 2019-01-08 2020-01-08 S1p₁ 수용체와 관련된 병태의 치료 방법 Active KR102958419B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789937P 2019-01-08 2019-01-08
US62/789,937 2019-01-08
PCT/US2020/012783 WO2020146529A1 (en) 2019-01-08 2020-01-08 Methods of treating conditions related to the s1p1 receptor

Publications (2)

Publication Number Publication Date
KR20210113298A KR20210113298A (ko) 2021-09-15
KR102958419B1 true KR102958419B1 (ko) 2026-04-28

Family

ID=69467760

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217024973A Active KR102958419B1 (ko) 2019-01-08 2020-01-08 S1p₁ 수용체와 관련된 병태의 치료 방법

Country Status (10)

Country Link
US (1) US20220142977A1 (cg-RX-API-DMAC7.html)
EP (1) EP3908276B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022516662A (cg-RX-API-DMAC7.html)
KR (1) KR102958419B1 (cg-RX-API-DMAC7.html)
CN (2) CN113874009A (cg-RX-API-DMAC7.html)
AU (1) AU2020206700A1 (cg-RX-API-DMAC7.html)
CA (1) CA3124701A1 (cg-RX-API-DMAC7.html)
IL (1) IL284114A (cg-RX-API-DMAC7.html)
MX (1) MX2021008263A (cg-RX-API-DMAC7.html)
WO (1) WO2020146529A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
ES2951870T3 (es) * 2018-10-03 2023-10-25 Arena Pharm Inc Etrasimod para su uso en procedimientos para el tratamiento de la esclerodermia
MX2021008263A (es) 2019-01-08 2021-10-13 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
WO2025177319A2 (en) * 2024-02-22 2025-08-28 Msn Laboratories Private Limited, R&D Center Solid state forms of L-Arginine, (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetate and processes for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (zh) 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
PL2342205T4 (pl) * 2008-08-27 2016-12-30 Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬
MX2021008263A (es) 2019-01-08 2021-10-13 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Also Published As

Publication number Publication date
CN118976023A (zh) 2024-11-19
AU2020206700A1 (en) 2021-07-15
US20220142977A1 (en) 2022-05-12
WO2020146529A1 (en) 2020-07-16
CA3124701A1 (en) 2020-07-16
MX2021008263A (es) 2021-10-13
KR20210113298A (ko) 2021-09-15
IL284114A (en) 2021-08-31
CN113874009A (zh) 2021-12-31
JP2022516662A (ja) 2022-03-01
EP3908276B1 (en) 2025-06-11
EP3908276A1 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
EP3908276B1 (en) Methods of treating conditions related to the s1p1 receptor
KR102824401B1 (ko) S1p1 수용체와 관련된 병태의 치료 방법
JP7219732B2 (ja) S1p1受容体に関連する状態の処置方法
ES2987794T3 (es) Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
JP2023552828A5 (cg-RX-API-DMAC7.html)
TWI646960B (zh) 慢性腎臟病之進展抑制或改善用製劑
JP2025507156A (ja) 処置方法
HK40116740A (en) Methods of treating conditions related to the s1p1 receptor
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
JP2022550458A (ja) S1p1受容体に関連する状態を処置する方法
HK40116488A (en) Methods of treating conditions related to the s1p1 receptor
KR20200021479A (ko) 페마피브레이트를 함유하는 의약
WO2026043678A1 (en) Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy
JP2026516050A (ja) 多発性硬化症を治療するためのbtk阻害剤
TW202339718A (zh) 治療方法
CN120112284A (zh) 阿达格拉西布固体药物组合物
EP4054572A1 (en) Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)